Content about Doxycycline

March 6, 2014

Lupin on Thursday announced that it received final approval from the Food and Drug Administration for both its doxycycline capsules and its ciprofloxacin for oral suspension.

MUMBAI and BALTIMORE — Lupin on Thursday announced that it received final approval from the Food and Drug Administration for its doxycycline capsules USP, 50 mg, 75 mg and 100 mg, which is the generic version of Aqua Pharmaceuticals' Monodox capsules. The drug is used to treat infections caused by various microorganisms and as an adjunctive therapy in severe acne, according to the company.

July 31, 2013

The Food and Drug Administration has given Lupin Pharmaceuticals tentative approval to two of its products, the company said Wednesday.

BALTIMORE — The Food and Drug Administration has given Lupin Pharmaceuticals tentative approval to two of its products, the company said Wednesday.

Lupin announced the tentative approvals for armodafinil tablets in the 50-mg, 100-mg, 150-mg, 200-mg and 250-mg strengths and doxycycline capsules in the 40-mg strength. Tentative approval means that the drugs meet the FDA's conditions for approval, but can't be marketed yet due to patent or market exclusivity protection that has yet to expire.

April 16, 2013

The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

DUBLIN — The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

Warner Chilcott announced the approval of the 200-mg strength of Doryx (doxycycline hyalite) delayed-release tablets, which the company plans to release in July 2013.

Doryx delayed-release tablets are already available in the 75-mg, 100-mg and 150-mg strengths.

 

July 10, 2012

Generic drug maker Mylan is suing Warner Chilcott and an Australian company, alleging that they illegally tried to protect one of their drugs from generic competition, according to published reports.

NEW YORK — Generic drug maker Mylan is suing Warner Chilcott and an Australian company, alleging that they illegally tried to protect one of their drugs from generic competition, according to published reports.

Reuters reported that Mylan filed a suit against Warner Chilcott and Mayne Pharma Group over the antibiotic and acne drug Doryx (doxycycline), saying they made minor and insignificant changes to the drug so that approval of generic versions would be delayed.

May 1, 2012

Generic drug maker Mylan has released a version of a drug used to treat bacterial infections, the company said.

PITTSBURGH — Generic drug maker Mylan has released a version of a drug used to treat bacterial infections, the company said.

Mylan announced the launch of doxycycline hyclate delayed-release tablets in the 150-mg strength. The launch follows a decision by the U.S. District Court for the District of New Jersey that Mylan's product did not infringe patents covering the drug's branded version, Doryx. Warner Chilcott, which markets Doryx, had brought the case.

February 9, 2012

The Food and Drug Administration has approved an antimicrobial drug made by Mylan, the drug maker said Thursday.

PITTSBURGH — The Food and Drug Administration has approved an antimicrobial drug made by Mylan, the drug maker said Thursday.

The FDA approved Mylan's doxycycline hyalite delayed-release tablets in the 150-mg strength. The drug is a generic version of Warner Chilcott's Doryx.

September 22, 2011

A federal court in New Jersey has blocked an attempt by Mylan to market a generic version of a drug made by Warner Chilcott.

DUBLIN — A federal court in New Jersey has blocked an attempt by Mylan to market a generic version of a drug made by Warner Chilcott.

Warner Chilcott announced Thursday that the U.S. District Court for the District of New Jersey granted its motion for a preliminary injunction against Mylan to prevent it from launching a generic version of the antibiotic Doryx (doxycycline) in the 150-mg strength until the court makes a decision relating to a patent covering the drug, which Warner Chilcott and Mayne Pharmaceuticals allege Mylan to have infringed.

August 30, 2011

Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

NEW YORK — Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

March 4, 2011

SUPPLIER NEWS — Impax Labs received regulatory approval from the Food and Drug Administration for its generic version of a bacterial infection treatment. The drug maker said the FDA approved its 150-mg doxycycline monohydrate capsules, a drug used to treat bacterial infections and a generic version of Adoxa, made by Nycomed subsidiary PharmaDerm. The 150-mg strength of Adoxa had sales of about $25 million during the 12 months ended in December 2010, according to Wolters Kluwer.